<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199953</url>
  </required_header>
  <id_info>
    <org_study_id>RAB-USA-57</org_study_id>
    <secondary_id>IRB numbers:</secondary_id>
    <secondary_id>FMLH # 02-033</secondary_id>
    <secondary_id>HRRC # 056-02</secondary_id>
    <nct_id>NCT00199953</nct_id>
  </id_info>
  <brief_title>Post-nasal Drainage as an Extraesophageal Manifestation of Reflux</brief_title>
  <official_title>Post-nasal Drainage as an Extraesophageal Manifestation of Reflux</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho-McNeil, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <brief_summary>
    <textblock>
      Objectives of this study are:&#xD;
&#xD;
        -  To quantitatively evaluate the relationship between extraesophageal manifestations of&#xD;
           gastroesophageal reflux (EER) and postnasal drainage(PND)in a group of patients without&#xD;
           radiographic or endoscopic evidence of sinonasal inflammatory disease.&#xD;
&#xD;
        -  To assess the efficacy of BID proton pump inhibitors (PPI) in the management of patients&#xD;
           with symptomatic postnasal drainage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroesophageal reflux disease(GERD) is a common disorder of the esophagus, affecting 7-10%&#xD;
      of the U.S. population. Characteristic symptoms include heartburn, chest pain, and&#xD;
      indigestion. EER denotes gastroesophageal refluxate that reaches structures above the upper&#xD;
      esophageal sphincter. EER has been implicated in the pathogenesis of several otolaryngologic&#xD;
      disorders such as chronic posterior laryngitis, laryngeal contact ulcer or granuloma,&#xD;
      paroxysmal laryngospasm, vocal cord nodules, Reinke's edema, subglottic or laryngotracheal&#xD;
      stenosis, globus pharyngeus,and laryngeal and hypopharyngeal carcinoma. In addition, EER has&#xD;
      been associated with disorders of both the lower and upper respiratory tract and with chronic&#xD;
      sinonasal inflammation.&#xD;
&#xD;
      Patients with EER rarely complain of the common symptoms of GERD, such as heartburn. Often&#xD;
      they present with symptoms involving the larynx and pharynx, including throat-clearing,&#xD;
      globus pharyngeus, and postnasal drainage. These symptoms may be present due to direct&#xD;
      irritation of the nasal epithelium by gastric refluxate and/or a neurogenic inflammatory&#xD;
      process mediated by the autonomic nervous system.&#xD;
&#xD;
      Specific Aims:&#xD;
&#xD;
        -  Specific Aim 1: To establish the relation ship between EER and PND in patients without&#xD;
           sinonasal inflammatory disease.&#xD;
&#xD;
        -  Hypothesis 1: In patients without radiographic or endoscopic evidence of sinonasal&#xD;
           inflammatory disease, PND is a symptom of EER.&#xD;
&#xD;
        -  Method 1: We will test this hypothesis utilizing a 2-site 24-hour pH probe test in a&#xD;
           symptomatic patient group and compare then to a previously tested age and sex-matched&#xD;
           control group.&#xD;
&#xD;
        -  Specific Aim 2: To establish the efficacy of PPI in the management of PND.&#xD;
&#xD;
        -  Hypothesis 2: Patients with a chief complaint of PND and no sinonasal inflammatory&#xD;
           disease will improve with 3-month PPI treatment with Rabeprazole 20 mg twice a day.&#xD;
&#xD;
        -  Method 2: A group of patients with a chief complaint of postnasal drainage, without&#xD;
           radiographic or endoscopic evidence of sinonasal inflammatory disease will be entered&#xD;
           into a prospective placebo-controlled trial utilizing BID PPIs over a 3-month period.&#xD;
           the primary outcome measures will be: 1) Visual analog Scales, assessing the severity&#xD;
           and frequency of PND at days 0 and 90 of treatment and 2)A quantitative color analysis&#xD;
           of laryngeal erythema, utilizing videolaryngoscopy at days 0 and 90 of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- VAS1:Visual Analog Scale indicating severity of PND</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>- VAS2:Visual Analog Scale indicating frequency of PND</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>- VAS3:Visual Analog Scale indicating frequency of throat-clearing.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Two-site 24-hour pH probe test indicating presence or gastroesophageal reflux episodes.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Videolaryngoscopy for quantitative color analysis evaluation of laryngeal erythema as index of EER.</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Postnasal Drainage</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole 20 mg twice a day for 90-day period treatment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 and &lt;70;&#xD;
&#xD;
          -  PND as chief complaint;&#xD;
&#xD;
          -  No known acute or chronic sinus disease;&#xD;
&#xD;
          -  Nonsmokers;&#xD;
&#xD;
          -  Subjects with no history of esophageal or gastric surgery&#xD;
&#xD;
          -  Subjects with no history of allergic disease&#xD;
&#xD;
          -  Women non pregnant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age , 18 or &gt; 70;&#xD;
&#xD;
          -  No PND as chief complaint&#xD;
&#xD;
          -  Al;ergic disease or acute or chronic sinus disease;&#xD;
&#xD;
          -  Smokers;&#xD;
&#xD;
          -  Pregnant women;&#xD;
&#xD;
          -  Subjects with history of esophageal or gastric surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd A Loehrl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ulualp SO, Toohill RJ. Laryngopharyngeal reflux: state of the art diagnosis and treatment. Otolaryngol Clin North Am. 2000 Aug;33(4):785-802. Review.</citation>
    <PMID>10918661</PMID>
  </reference>
  <reference>
    <citation>Lodi U, Harding SM, Coghlan HC, Guzzo MR, Walker LH. Autonomic regulation in asthmatics with gastroesophageal reflux. Chest. 1997 Jan;111(1):65-70.</citation>
    <PMID>8995994</PMID>
  </reference>
  <reference>
    <citation>Chambers DW, Davis WE, Cook PR, Nishioka GJ, Rudman DT. Long-term outcome analysis of functional endoscopic sinus surgery: correlation of symptoms with endoscopic examination findings and potential prognostic variables. Laryngoscope. 1997 Apr;107(4):504-10.</citation>
    <PMID>9111381</PMID>
  </reference>
  <reference>
    <citation>Ulualp SO, Toohill RJ, Hoffmann R, Shaker R. Possible relationship of gastroesophagopharyngeal acid reflux with pathogenesis of chronic sinusitis. Am J Rhinol. 1999 May-Jun;13(3):197-202.</citation>
    <PMID>10392238</PMID>
  </reference>
  <reference>
    <citation>Jaradeh SS, Smith TL, Torrico L, Prieto TE, Loehrl TA, Darling RJ, Toohill RJ. Autonomic nervous system evaluation of patients with vasomotor rhinitis. Laryngoscope. 2000 Nov;110(11):1828-31.</citation>
    <PMID>11081594</PMID>
  </reference>
  <reference>
    <citation>Smit CF, Tan J, Devriese PP, Mathus-Vliegen LM, Brandsen M, Schouwenburg PF. Ambulatory pH measurements at the upper esophageal sphincter. Laryngoscope. 1998 Feb;108(2):299-302.</citation>
    <PMID>9473087</PMID>
  </reference>
  <reference>
    <citation>Hanson DG, Jiang J, Chi W. Quantitative color analysis of laryngeal erythema in chronic posterior laryngitis. J Voice. 1998 Mar;12(1):78-83.</citation>
    <PMID>9619981</PMID>
  </reference>
  <reference>
    <citation>El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol. 2001 Apr;96(4):979-83.</citation>
    <PMID>11316215</PMID>
  </reference>
  <reference>
    <citation>Smith TL, Correa AJ, Kuo T, Reinisch L. Radiofrequency tissue ablation of the inferior turbinates using a thermocouple feedback electrode. Laryngoscope. 1999 Nov;109(11):1760-5.</citation>
    <PMID>10569403</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <keyword>Postnasal drainage</keyword>
  <keyword>Extraesophageal reflux</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

